Dr. Gannon joined NeuroPhage as Vice President of Preclinical Research and Development in October, 2009. Dr. Gannon received a PhD in Neuroscience in 1994 from The Florida State University and conducted her postdoctoral training at Hoffman La-Roche in the Institute of Molecular Biology and at Mount Sinai School of Medicine in the Department of Physiology and Biophysics. She has over 15 years of drug discovery and development experience at major pharmaceutical firms as well as start-up ventures. Her primary focus is on preclinical efficacy and animal models of neuropsychiatric disorders. Dr. Gannon’s career has spanned the breadth of drug development from early discovery to working on approved CNS drugs such as Requip (GSK) and Zyprexa (Lilly). At Lilly, Dr. Gannon headed up a behavioral pharmacology laboratory in Neuroscience Drug Discovery. Her group focused on learning and memory and supported various Alzheimer’s disease drug development programs. Since moving to the Boston area in 2003, she has worked for several early stage ventures, including CereMedix where she was VP of Development and Predix (post-merger - EPIX) Pharmaceuticals where she served as Senior Director of Biology and was responsible for preclinical efficacy and the global outsourcing of in vitro and in vivo studies for neurologic, psychiatric and obesity drug programs. Following EPIX, she headed up the US division of Eolas Biosciences, a company devoted to accelerating drug development efforts through external research alliances and strategic outsourcing.